Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Study sponsor: Candel Therapeutics, Inc. · CADL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-10-22Estimated
Enrollment · participants500Estimated
Source updated2026-06-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.